GSK has axed a Phase 2 study of a chronic hepatitis B therapeutic vaccine, adding to a string of treatment R&D hurdles for the liver infection.

Shares of GSK PLC GSK advanced 1.98% to £13.68 Tuesday, on what proved to be an all-around positive trading session for the ...

Mar Vista Investment Partners, LLC, an investment management company, released the “Strategic Growth Strategy” third quarter ...

Berenberg lowered the firm’s price target on GSK (GSK) to 1,600 GBp from 1,820 GBp and keeps a Buy rating on the shares.Don't Miss our Black ...

This writer takes a look at a beaten down FTSE 100 stock that has been sliding lower. Has it reached his Buy zone yet or is ...

GSK has brought its message about the risks of antimicrobial resistance (AMR) to commuters in London. | GSK has brought its ...

Although the FDA has expanded approvals for two respiratory syncytial virus (RSV) vaccines to include high-risk young and ...

Shares of GSK PLC GSK inched down 0.41% to £13.35 Friday, on what proved to be an all-around positive trading session for the ...

We are grateful to our colleagues for their interest and thoughtful comments on our Seminar about systemic lupus erythematosus (SLE).1 We appreciate the remarks from Qihe Xu, and Thomas Pabst and ...

GSK (GSK) announced that the European Commission, EC, has approved a single-vial, fully liquid presentation of Menveo to help protect against ...

(Alliance News) - GSK PLC on Wednesday said its meningitis vaccine, Menveo, has received approval from the European Commission in a new single-vial, fully liquid presentation.

Pitcairn Co. cut its holdings in GSK plc (NYSE:GSK – Free Report) by 14.1% during the 3rd quarter, according to its most ...